2022 World Conference on Lung Cancer (ePosters)-EP08.01-070. Safety and Efficacy of Sitravatinib + Tislelizumab in Patients with PD-L1+, Locally Advanced/Metastatic, Squamous NSCLC

EP08.01-070. Safety and Efficacy of Sitravatinib + Tislelizumab in Patients with PD-L1+, Locally Advanced/Metastatic, Squamous NSCLC

Back to course

Pdf Summary

In a phase 1b study, the safety and efficacy of sitravatinib plus tislelizumab were evaluated in patients with PD-L1-positive, locally advanced or metastatic, squamous non-small cell lung cancer (NSCLC). The study enrolled 24 patients, and all patients were included in the safety analysis set, while 23 patients were included in the efficacy-evaluable analysis set. The primary endpoint of the study was safety and tolerability.<br /><br />The median age of the patients was 65.0 years, and the majority were male. The median study follow-up was 9.5 months. Treatment-emergent adverse events (TEAEs) of any grade and grade 3 were reported in 95.8% and 66.7% of patients, respectively. Treatment-related adverse events (TRAEs) of any grade and grade 3 were reported in 91.7% and 62.5% of patients, respectively. The most common grade 3 TEAE and TRAE was hypertension. TEAEs leading to discontinuation of sitravatinib or tislelizumab were observed in some patients.<br /><br />In terms of efficacy, in the efficacy-evaluable population, the confirmed objective response rate (ORR) was 30.4%, with all seven patients achieving a partial response. The disease control rate was 78.3%. Median progression-free survival (PFS) was 5.4 months, and median overall survival (OS) was not reached.<br /><br />Overall, sitravatinib plus tislelizumab demonstrated a manageable safety profile, with promising antitumor activity in patients with PD-L1-positive, squamous NSCLC. These results support the ongoing phase 3 study investigating this combination therapy in advanced NSCLC.<br /><br />In conclusion, the combination of sitravatinib plus tislelizumab showed potential as a treatment option for patients with PD-L1-positive, locally advanced or metastatic, squamous NSCLC, providing a manageable safety profile and promising antitumor activity.

Asset Subtitle

Jun Zhao

Meta Tag

Speaker Jun Zhao

Topic Metastatic Non-small Cell Lung Cancer - Immunotherapy

Keywords

phase 1b study

sitravatinib

tislelizumab

PD-L1-positive

locally advanced

metastatic

squamous non-small cell lung cancer

safety and efficacy

adverse events

objective response rate